A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI with Next-Generation Propellant Compared With BGF MDI with HFA propellant

Trial Identifier: D5985C00004
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: October 2022
Primary Completion Date: April 2023
Study Completion Date: April 2023
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
US, CA Glendale, CA, US, 91206